Summer Study Sample Clauses

Summer Study. Teachers may be released for summer study without pay before the close of school in June or after the opening of school in the fall, if absolutely necessary. Request shall be submitted on the designated form at least five (5) weeks prior to the date of absence. Teachers shall receive written approval from their Adult Education manager, and request should then be submitted to the Human Resources Department.
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Summer Study. Section H Other Leaves Subd. 1 Legal Reasons Subd. 2 Military Subd. 3. Peace Corps/VISTA
Sample 1Sample 2
Summer Study. The summer study rate will be $20.00 per hour. SUMMER WORKSHOPS Teachers who are asked by the District to attend a summer workshop will be reimbursed $15.00 per hour by the District. Teachers will not be paid for workshops they choose to attend on their own. ART - MUSIC Elementary special area teachers (art and music) shall receive a stipend of $125 for every evening or outside of teacher work day student program beyond the first such program in a school year. To be eligible for the stipend, the building principal must approve the program. ALTERNATIVE EDUCATION INSTRUCTOR The rate will be $25.00 per hour. Job Descriptions - Job descriptions are available upon request. ****With the exception of Building Level Stipends, no supplemental will be split more than two ways.
Sample 1
Summer Study. No joint committee shall meet on school time without the express consent of the Superintendent. When a joint committee is meeting with a specific recommendation as a goal, the Superintendent, after consultation with the chairpersons, may establish a time line for the development of the recommendation. Each of the two (2) groups of representatives on any joint committee shall be entitled to one (1) vote on the final recommendations of the committee. The Association and the Administration co-chairpersons shall sign the recommendation of the joint committee indicating the committee’s approval of said recommendation. The co-chairpersons shall then forward this recommendation of the joint committee to the Association President. If the approved recommendation of a joint committee is not accepted by the Association, it shall be referred back to the committee for further study. If the approved recommendation is accepted by the Association, the committee co-chairpersons will be so informed by the President of the Association. After receiving the notification of such acceptance, the co- chairpersons shall forward the recommendation to the Superintendent. If such recommendation is rejected by the Superintendent, in whole or in part, the Superintendent shall give written reasons to the committee, with a copy to the Association, within twenty (20) school days of the submission of the recommendation to him/her. Where a recommendation from a joint committee which requires Board approval is judged by the Superintendent and the President of the Association to require amendment of the contract, then the Board shall be advised of this fact before acting upon the recommendation. Where the Superintendent and the President do not agree that such action upon a recommendation would require amendment of the contract, then the Board shall be so advised.
Sample 1
Summer Study. A subset of “Meeting,” which is a gathering of XXXXX members for 8-10 weeks during the summer.
Sample 1

Related to Summer Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.

  • Feasibility Study 4.3.1 The Feasibility Study shall identify any potential adverse system impacts that would result from the interconnection of the Generating Facility.

  • The Study 2.1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

Time is Money Join Law Insider Premium to draft better contracts faster.